Antineoplaston Therapy in Treating Patients With Primary Central Nervous System Lymphoma

NCT00003505 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Conditions

Primary Central Nervous System Lymphoma

Interventions

DRUG: antineoplaston A10
DRUG: antineoplaston AS2-1
PROCEDURE: alternative product therapy
PROCEDURE: biological therapy
PROCEDURE: biologically based therapies
PROCEDURE: cancer prevention intervention
PROCEDURE: complementary and alternative therapy
PROCEDURE: differentiation therapy

Sponsor

Burzynski Research Institute